BioVie Inc. (BIVI) - Q1 2025 (Ended Sept 30, 2024) Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2024. BioVie Inc. is a clinical-stage biopharmaceutical company developing therapies for neurodegenerative disorders (Alzheimer's and Parkinson's disease) and liver disease. The company is currently pre-revenue, with operations focused on clinical trials for its lead candidates, bezisterim (NE3107) and BIV201 (terlipressin).
Key Financial Metrics
| Metric | Q1 2025 (Sept 30, 2024) | Q1 2024 (Sept 30, 2023) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(4.15) million | $(10.71) million |
| Net Loss Per Share (Basic/Diluted) | $(0.70) | $(2.92) |
| Operating Expenses | $4.12 million | $10.88 million |
| Cash and Cash Equivalents | $20.02 million | $21.21 million |
| Working Capital | $13.31 million | $14.69 million |
| Debt (Current Note Payable, net) | $3.32 million | $5.70 million |
| Stockholders' Equity | $14.07 million | $7.55 million |
Material Changes vs. Prior Period
- Significant Reduction in Net Loss: Net loss decreased by approximately $6.5 million year-over-year, primarily driven by a $6.9 million reduction in Research and Development (R&D) expenses. This decline is attributed to the completion of major clinical trials in the prior fiscal year.
- R&D Expense Breakdown: R&D expenses fell from $8.88 million to $1.99 million. The decrease included a $5.2 million reduction in clinical trial costs, lower clinical team payroll, and reduced consultant fees. This was partially offset by $155,000 in increased Chemistry, Manufacturing, and Controls (CMC) expenses.
- SG&A Increase: Selling, General, and Administrative expenses increased by $132,000 to $2.07 million, largely due to higher legal fees associated with regulatory filings and the ongoing securities class action litigation.
- Debt Repayment: The company repaid $2.5 million of its principal loan balance to Avenue Venture Opportunities Fund during the quarter. The remaining principal balance is $2.5 million, due in three monthly installments.
- Capital Raises: The company raised approximately $3.0 million in gross proceeds from a public offering in September 2024. Additionally, a 1:10 reverse stock split was effected in August 2024.
Outlook, Risks, and Contingencies
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. The company has an accumulated deficit of $338.7 million and no revenue. Future operations depend on securing additional financing through equity sales, loans, or strategic transactions.
- Clinical Pipeline Updates:
- Alzheimer's Disease: The Phase 3 trial for bezisterim was underpowered due to the exclusion of 15 sites with protocol violations. The company is evaluating adaptive trial features or designing a new Phase 3 study.
- Long COVID: Received a $13.1 million grant from the U.S. Department of Defense. The trial is expected to commence in early 2025.
- Parkinson's Disease: FDA authorized a new Phase 2 study protocol in August 2024.
- Liver Disease: Finalizing Phase 3 protocol designs for BIV201 for refractory ascites following FDA guidance.
- Legal Proceedings: A consolidated securities class action lawsuit (In re BioVie Inc. Securities Litigation) alleges misrepresentations regarding the Phase 3 Alzheimer's trial. The company filed a motion to dismiss in August 2024; the reply brief is due December 5, 2024. The company believes the claims are without merit.
- Subsequent Events: In October 2024, the company closed three registered direct offerings raising approximately $15.9 million in gross proceeds. Additionally, $1.9 million was raised from the exercise of warrants from the September offering.
Investor Verification Checklist
- Cash Runway: Verify the updated cash position post-October 2024 capital raises ($15.9M) against the burn rate to assess the timeline for future funding needs.
- Debt Maturity: Confirm the repayment schedule for the remaining $2.5 million Avenue loan, which matures in December 2024.
- Class Action Status: Monitor the outcome of the motion to dismiss in the securities class action lawsuit, as a loss could result in significant financial liability.
- Alzheimer's Trial Strategy: Review the final decision on the Phase 3 Alzheimer's trial design (adaptive enrollment vs. new study) and associated costs.
- Dilution Impact: Assess the impact of the October 2024 offerings and outstanding warrants (over 4.3 million shares) on existing shareholder equity.